PTO-1390. (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES			ATTORNEY'S DOCKET NUMBER				
DESIGNATED/ELECTED OFFICE (DO/EO/US)			U.S. APPLICATION NO. (If known, see 37 CFR 1.5)				
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371			10/541.468				
INTERNATI	ONAL APPLICATION NO.	_ INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED				
PCLIEP	2004/000539	January 23, 2004	January 31, 2003				
Single Nucleotide Polymorphisms as Predictive Diagnostics For Adverse Drug Reactions (ADR) & Drug Efficacy							
APPLICAN*	r(s) for do/ed/us		Wisc had renton sinux) & Budga Henry				
	Stephen						
Applicant I	nerewith submits to the United St	ates Designated/Elected Office (DO/EC	O/US) the following items and other information:				
1. 🔲 TI	1. This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.						
	2.  This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.						
	3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.						
4. L T	he US has been elected (Article 31).						
5.	A copy of the International Application	in as filed (35 U.S.C. 371(c)(2))					
		d only if not communicated by the Internation	nal Bureau).				
	b has been communicated b						
	c. is not required, as the application was filed in the United States Receiving Office (RO/US).						
6. 📖		ne International Application as filed (35 U.S.	C. 3/1(c)(2)).				
	a. is attached hereto.						
7.	b. has been previously submitted under 35 U.S.C. 154(d)(4).						
, <u> </u>	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))						
	a.  are attached hereto (required only if not communicated by the International Bureau).  b. have been communicated by the International Bureau.						
	<ul> <li>b.  have been communicated by the International Bureau.</li> <li>c.  have not been made; however, the time limit for making such amendments has NOT expired.</li> </ul>						
i	d. have not been made and will not be made.						
8. 🗆	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).						
9. 🔀	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).						
10.	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).						
Items	11 to 20 below concern document(	s) or information included:					
11.	An Information Disclosure Statemen	nt under 37 CFR 1.97 and 1.98.					
12.	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.						
13. 🔲	A preliminary amendment.						
14. 🖳	An Application Data Sheet under 37 CFR 1.76.						
15.	A substitute specification.						
16.	A power of attorney and/or change of address letter.						
17.	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.						
18. 🗀		ernational Application under 35 U.S.C. 154(d					
19. 🖵	A second copy of the English language	age translation of the international application	on under 35 U.S.C. 154(d)(4).				

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)			INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER		
10/541,468			PCT IEP 2004/	PCT IEP 2004/000539		Lea 36562-45	
20. Other items or information:							
						l	
The foll	owing fees have b	een submitted			CALCULATIONS	PTO USE ONLY	
21. 🗌 Basi	c national fee (37	CFR 1.492(a))		\$300	\$		
22. Exam	nination fee (37 CF	R 1.492(c))					
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0  All other situations							
If the written opin IPEA/US Search fee (37 C International Sea	rch fee (37 CFR 1. lion of the ISA/US indicates all claim FR 1.445(a)(2)) had onal Searching Aut irch Report prepare	\$					
previously All other situation	y communicated to	the US by the IB		\$400 \$500			
	TOTAL OF 21, 22			·-			
Additional fe sequenc electroni	e for specification e listing in complia c medium) (37 CF s <b>\$250</b> for each ad						
Total Sheets	Extra Sheets	Number of each additional 50 or fraction RATE thereof (round up to a whole number)		RATE			
- 100 =	/50 =		× \$250		\$	·	
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).							
CLAIMS	NUMB	ER FILED	NUMBER EXTRA	RATE	\$		
Total claims		- 20 =		x \$ 50	\$		
Independent clai	ms	- 3 =		x \$200	\$		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360					\$		
		\$					
Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.							
		\$					
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).					\$		
TOTAL NATIONAL FEE =					\$		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property					\$		
		\$ 130.00					
					Amount to be refunded:	\$	
					Amount to be charged	\$	

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

а. 🗌	A check in the amount of \$ to cover the above	ve fees is enclosed.			
b. <b>X</b>	Please charge my Deposit Account No. <u>50–3508</u> in the amount of \$ <u>130 .00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.				
с. 🗶	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-3508. A duplicate copy of this sheet is enclosed.				
d. 🔲	Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.				
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.					
SEND A	ALL CORRESPONDENCE TO:				
04.1077	ALL SOUTHER ONDERSE TO.				
	W & PATENTS DEPARTMENT YER HEALTHCARE LLC	Mark Seles NAME			
	5 POTTER STREET RKELEY, CA 94710	44,330 REGISTRATION NUMBER			